Cargando…

Follistatin-Like 1: Growing Evidence for Its Beneficial Role in Heart Failure

Detalles Bibliográficos
Autor principal:	Wollert, Kai C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Editorial Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113344/ https://www.ncbi.nlm.nih.gov/pubmed/30167514 http://dx.doi.org/10.1016/j.jacbts.2016.05.001

Ejemplares similares

Hydrogen Sulfide Therapy Promotes Beneficial Systemic Effects in Experimental Heart Failure
por: Nabeebaccus, Adam A., et al.
Publicado: (2018)

A role for Follistatin-like protein 1 (FSTL1) in colorectal cancer
por: Voutsadakis, Ioannis A.
Publicado: (2020)

The Role of Macrophages in Nonischemic Heart Failure
por: Chen, Bijun, et al.
Publicado: (2018)

Follistatin-Like 1 Regulates Hypertrophy in Heart Failure With Preserved Ejection Fraction
por: Tanaka, Komei, et al.
Publicado: (2016)

Hypo-glycosylated follistatin-like 1 for new cardiomyocyte formation
por: Kerkelä, Risto
Publicado: (2022)

The Growing Case for Use of SGLT2i in Heart Failure: Additional Benefits of Empagliflozin in a HFpEF Rodent Model
por: Ha, Chae-Myeong, et al.
Publicado: (2019)

Role of ischemia-modified albumin in patients with acute decompensated heart failure
por: Pan, Defeng, et al.
Publicado: (2016)

Distal protection beneficial?
por: van der Wall, E. E., et al.
Publicado: (2009)

Empagliflozin and the Prevention of Heart Failure: Will Reverse Translation Lead to New Paradigms for the Treatment of Heart Failure?
por: Mann, Douglas L., et al.
Publicado: (2017)

The growing pains of ifosfamide
por: Sprangers, Ben, et al.
Publicado: (2020)

Heart rate in heart failure with mid-range ejection fraction
por: Yılmaz, Mehmet Birhan
Publicado: (2019)

A Growth Tonic for Heart Failure?
por: Bishopric, Nanette H.
Publicado: (2016)

Growing Evidence Linking Microvascular Dysfunction With Heart Failure With Preserved Ejection Fraction
por: Giamouzis, Gregory, et al.
Publicado: (2016)

Reconsidering Renal Sympathetic Denervation for Heart Failure
por: Tang, W.H. Wilson, et al.
Publicado: (2017)

Brain-derived neurotrophic factor in heart failure
por: Yılmaz, Mehmet Birhan
Publicado: (2019)

Oxytocin: A New Therapeutic for Heart Failure?
por: Habecker, Beth A.
Publicado: (2020)

Interleukin-1 Blockade in Acute Myocardial Infarction and Heart Failure: Getting Closer and Closer
por: Toldo, Stefano, et al.
Publicado: (2017)

Re: Scragg–Emerging Evidence of Thresholds for Beneficial Effects from Vitamin D Supplementation
por: Boucher, Barbara J, et al.
Publicado: (2019)

Cell Therapy for Heart Failure With Preserved Ejection Fraction
por: Borlaug, Barry A., et al.
Publicado: (2016)

Metabolic Coupling as a Therapeutic Strategy for Heart Failure
por: Young, Martin E.
Publicado: (2019)

Abnormal heart rate recovery in patients with heart failure: an important target for exercise training treatment
por: Dimopoulos, Stavros
Publicado: (2015)

Beyond lipid lowering: pleiotropic effects of statins in heart failure
por: Swenne, C. A.
Publicado: (2013)

Cardiometabolic Heart Failure and HFpEF: Still Chasing Unicorns
por: Sharp, Thomas E., et al.
Publicado: (2019)

Targeting Mitochondrial Function in Heart Failure: Makes Sense But Will it Work?
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2019)

Modulation of Glucagon Signaling: A Metabolic Approach for Heart Failure?
por: Pocai, Alessandro
Publicado: (2019)

Promoting Health Equity in Heart Failure Amid a Pandemic
por: DeFilippis, Ersilia M., et al.
Publicado: (2021)

Cardiac BIN1 Replacement Therapy Ameliorates Inotropy and Lusitropy in Heart Failure by Regulating Calcium Handling
por: Gambardella, Jessica, et al.
Publicado: (2020)

Stem cell therapy for heart disease: truly beneficial?
por: van der Wall, E. E.
Publicado: (2014)

Sauna bathing: a warm heart proves beneficial
por: van der Wall, E.E.
Publicado: (2015)

Follistatin-like 1 in development and human diseases
por: Mattiotti, Andrea, et al.
Publicado: (2018)

Fine Tuning Adenylyl Cyclase as a (Gene) Therapy for Heart Failure
por: Port, J. David, et al.
Publicado: (2016)

Are follistatin-like protein 1 and follistatin-like protein 3 associated with inflammatory processes in patients with familial Mediterranean fever?
por: Kaplan, Huseyin, et al.
Publicado: (2023)

Unraveling the Mechanisms by Which Calpain Inhibition Prevents Heart Failure Development
por: Wehrens, Xander H.T.
Publicado: (2018)

Does nitric oxide mediate the effects of ivabradine in patients with heart failure?
por: Mączewski, Michał
Publicado: (2018)

Heart failure guidelines implementation: Lifting barriers using registries and networks
por: Keramida, Kalliopi, et al.
Publicado: (2020)

Understanding Heart Failure With Preserved Ejection Fraction in a Diabetic Way
por: Li, Haobo, et al.
Publicado: (2021)

Role of follistatin-like 1 levels and functions in calcific aortic stenosis
por: Zhang, Qianru, et al.
Publicado: (2023)

Is Atrial Fibrillation Ablation Really Beneficial in Patients with Heart Failure?
por: Kim, Jin-Bae, et al.
Publicado: (2021)

Clinical evaluation of heart failure patients: what good are biomarkers bringing us?
por: de Boer, R. A.
Publicado: (2014)

To implant or not to implant?: That is the unsolved question concerning heart failure patients with non-LBBB
por: Zarse, M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_201n1nd0r0b6mk1611hk4k7vn8